2349
We report a 71-year male with castration-resistant metastatic prostate cancer who was treated with weekly docetaxel for 12 weeks and developed significant eye irritation and dryness during treatment.
 a 71-year male with castration-resistant metastatic prostate cancer: Subject; 71-year: Subject.Age; male: Subject.Gender; significant eye irritation and dryness: Effect; weekly docetaxel for 12 weeks: Treatment; castration-resistant metastatic prostate cancer: Treatment.Disorder; docetaxel: Treatment.Drug; weekly: Treatment.Freq; 12 weeks: Treatment.Duration
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 a 71-year male with castration-resistant metastatic prostate cancer: Subject; 71-year: Subject.Age; male: Subject.Gender; significant eye irritation and dryness: Effect; weekly docetaxel for 12 weeks: Treatment; castration-resistant metastatic prostate cancer: Treatment.Disorder; docetaxel: Treatment.Drug; weekly: Treatment.Freq; 12 weeks: Treatment.Duration